Synthimed Labs Private Ltd, based in India, is a pharmaceutical company that stands out with its certifications from EDQM and WHO-GMP.
One of their notable products is NATEGLINIDE USP, with a corresponding US DMF Number 20231.
Remarkably, this DMF maintains an Active status since its submission on January 27, 2007, highlighting commitment to regulatory compliance.
Their GDUFA DMF Review was successfully complete, with a review date of July 30, 2013, and payment made on December 21, 2012, indicating their dedication to facilitating drug approvals, Categorized as Type II